Ibuprofen linked to lower endometrial cancer risk

New research indicates that regular use of ibuprofen, a common painkiller, may reduce the risk of endometrial cancer by up to 25% in certain women. This finding comes from a large-scale study analyzing over 42,000 participants, highlighting the drug's anti-inflammatory properties. However, experts caution against using it for prevention due to potential side effects.

Ibuprofen, a widely used non-steroidal anti-inflammatory drug (NSAID), has been associated with a decreased risk of endometrial cancer, the most common type of womb cancer affecting postmenopausal women. A 2025 analysis from the Prostate, Lung, Colorectal, and Ovarian (PLCO) study examined data from more than 42,000 women aged 55 to 74 over 12 years. Women who took at least 30 ibuprofen tablets per month showed a 25% lower risk of developing the cancer compared to those taking fewer than four tablets monthly. The protective effect was particularly strong among women with heart disease.

Endometrial cancer often links to risk factors like obesity, which raises estrogen levels that can promote cell growth in the uterus lining. Other factors include older age, diabetes, hormone replacement therapy, polycystic ovary syndrome, early menstruation, late menopause, or nulliparity. Symptoms may involve abnormal vaginal bleeding, pelvic pain, or discomfort during intercourse.

The drug's mechanism involves blocking cyclooxygenase (COX) enzymes, especially COX-2, which reduces inflammation-driving prostaglandins. This action may slow tumor development and affect cancer-related genes such as HIF-1α, NFκB, and STAT3, making cells more vulnerable to low oxygen or treatments. Broader evidence suggests ibuprofen could lower risks for bowel, breast, lung, and prostate cancers, and reduce bowel cancer recurrence.

Unlike ibuprofen, aspirin did not show similar benefits for endometrial cancer, though it may help prevent bowel cancer return. Other NSAIDs, like naproxen, have been studied for colon, bladder, and breast cancers, with effects varying by type, genetics, and health.

Conflicting results exist: one study of 7,751 patients found aspirin use after diagnosis increased mortality, especially in prior users. A review noted NSAIDs might reduce some cancer risks but raise kidney cancer chances with regular use.

Experts emphasize that long-term ibuprofen use risks stomach ulcers, gastrointestinal bleeding, kidney damage, heart attacks, or strokes. It interacts with drugs like warfarin. Prevention should prioritize lifestyle changes—healthy weight, activity, anti-inflammatory diet—over self-medication. Future research may clarify its role in high-risk groups.

相关文章

A woman undergoing chemotherapy performs home exercises in her living room to ease chemo brain symptoms.
AI 生成的图像

Home-based exercise program may ease “chemo brain” symptoms during chemotherapy, Phase II trial suggests

由 AI 报道 AI 生成的图像 事实核查

A Phase II randomized trial found that a six-week, home-based walking and resistance program improved attention test performance and reduced reports that others noticed cognitive problems among patients receiving chemotherapy. Low-dose ibuprofen improved some attention measures but showed mixed results on memory outcomes. The study was published in Cancer.

An antioxidant called L-ergothioneine, found in certain mushrooms, reduced period pain in a small study of 40 women. Participants took a daily 120-milligram supplement over three menstrual cycles, reporting lower pain scores compared to a placebo group. The findings suggest it targets oxidative stress in uterine cells.

由 AI 报道

Women taking GLP-1 medications such as Ozempic and Wegovy showed about 30 percent lower odds of developing breast cancer in a large observational study.

Some cancer patients take biotin supplements hoping to improve hair and nail growth, but specialists at Ohio State University Wexner Medical Center warn that high-dose biotin can interfere with certain blood tests used in cancer monitoring, potentially producing misleading results that could affect follow-up care.

由 AI 报道

Scientists at the University of Southern Denmark and Odense University Hospital have identified a previously unknown virus inside the common gut bacterium Bacteroides fragilis that appears more frequently in people with colorectal cancer. The finding, detailed by lead researcher Flemming Damgaard, resolves a long-standing paradox since the bacterium is also present in healthy individuals. While the link is strong, the virus's role in causing cancer remains unproven.

此网站使用 cookie

我们使用 cookie 进行分析以改进我们的网站。阅读我们的 隐私政策 以获取更多信息。
拒绝